{
  "pmid": "34058113",
  "uid": "34058113",
  "title": "In HFrEF, adding empagliflozin to medical therapy reduced a composite outcome, regardless of CKD status.",
  "abstract": "Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-Reduced. Circulation. 2021;143:310-21. 33095032.",
  "authors": [
    {
      "last_name": "Santos-Gallego",
      "fore_name": "Carlos G",
      "initials": "CG",
      "name": "Carlos G Santos-Gallego",
      "affiliations": [
        "Mount Sinai Hospital, New York, New York, USA (C.G.S.)."
      ]
    },
    {
      "last_name": "Van Spall",
      "fore_name": "Harriette G C",
      "initials": "HGC",
      "name": "Harriette G C Van Spall",
      "affiliations": [
        "McMaster University, Hamilton, Ontario, Canada (H.G.V.)."
      ]
    }
  ],
  "journal": {
    "title": "Annals of internal medicine",
    "iso_abbreviation": "Ann Intern Med",
    "issn": "1539-3704",
    "issn_type": "Electronic",
    "volume": "174",
    "issue": "6",
    "pub_year": "2021",
    "pub_month": "Jun"
  },
  "start_page": "JC68",
  "pages": "JC68",
  "language": "eng",
  "publication_types": [
    "Journal Article",
    "Comment"
  ],
  "keywords": [
    "Benzhydryl Compounds",
    "Glucosides",
    "Heart Failure",
    "Humans",
    "Renal Insufficiency, Chronic",
    "Stroke Volume"
  ],
  "article_ids": {
    "pubmed": "34058113",
    "doi": "10.7326/ACPJ202106150-068"
  },
  "doi": "10.7326/ACPJ202106150-068",
  "dates": {
    "completed": "2021-07-26",
    "revised": "2021-12-15"
  },
  "chemicals": [
    "Benzhydryl Compounds",
    "Glucosides",
    "empagliflozin"
  ],
  "grants": [],
  "search_metadata": {
    "search_type": "current_affiliation",
    "retrieved_date": "2025-07-30T15:04:22.798526",
    "pmid": "34058113"
  }
}